Table 2.
Characteristics of COVID-19 episodes.
| Directed treatment other than N/R |
p value N/R vs other directed treatment |
N/R |
p value N/R vs no/other non-directed tx |
No treatment/non-SARS-CoV-2 directed treatment |
Overall |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | % | n | |||
| SARS-CoV-2 variant of concern | 0.139 | 1.000 | ||||||||
| Wild type | 1 | 0.1 | 0 | 0.0 | 1 | 0.1 | 2 | 0.1 | ||
| Delta | 7 | 0.7 | 0 | 0.0 | 1 | 0.1 | 8 | 0.4 | ||
| Omicron | 479 | 47.9 | 44 | 37.6 | 281 | 37.9 | 804 | 43.2 | ||
| Not tested | 514 | 51.3 | 73 | 62.4 | 458 | 61.8 | 1045 | 56.2 | ||
| Symptoms at COVID-19 onset | 0.001 | <0.001 | ||||||||
| Pulmonary | 145 | 14.5 | 34 | 29.1 | 220 | 29.7 | 399 | 21.5 | ||
| Pulmonary + extrapulmonary | 176 | 17.6 | 32 | 27.4 | 121 | 16.3 | 329 | 17.7 | ||
| Extrapulmonary | 556 | 55.5 | 38 | 32.5 | 178 | 24.0 | 772 | 41.5 | ||
| Screening | 124 | 12.4 | 13 | 11.1 | 222 | 30.0 | 359 | 19.3 | ||
| COVID-19 infection | <0.001 | <0.001 | ||||||||
| Asymptomatic | 145 | 14.5 | 13 | 11.1 | 211 | 28.5 | 369 | 19.8 | ||
| Mild infection | 176 | 17.6 | 38 | 32.5 | 185 | 25.0 | 399 | 21.5 | ||
| Severe infection | 556 | 55.5 | 60 | 51.3 | 327 | 44.1 | 943 | 50.7 | ||
| Critical infection | 124 | 12.4 | 6 | 5.1 | 18 | 2.4 | 148 | 8.0 | ||
| Stay during COVID-19 episode | <0.001 | <0.001 | ||||||||
| Home | 264 | 26.4 | 59 | 50.4 | 554 | 74.8 | 877 | 47.2 | ||
| Hospital | 736 | 73.5 | 56 | 47.9 | 182 | 24.6 | 974 | 52.4 | ||
| Overall days of hospital stay | 12 (7–21) [1–135] | <0.001 | 8 (1–15) [1–57] | 0.975 | 7 (2–15) [1–118] | 11 (6–20) [1–135] | ||||
| ICU admission | 124 | 12.4 | 0.021 | 6 | 5.1 | 0.124 | 18 | 2.4 | 148 | 8.0 |
| Overall days in ICU | 9 (5–14) [1–68] | 0.609 | 7 (3–11) [2–32] | 0.323 | 3 (2–11) [1–24] | 9 (4–14) [1–68] | ||||
| COVID-19 treatment | ||||||||||
| Days under COVID-19 treatment | 2 (1–4) [1–34] | 4 (4–5) [1–24] | 4 (1–4) [1–34] | |||||||
| Days under nirmatrelvir/ritonavir treatment | 4 (4–5) [1–10] | 4 (4–5) [1–10] | ||||||||
| Days from COVID-19 onset to nirmatrelvir/ritonavir treatment | 1 (0–3) [0–151] | 1 (0–3) [0–151] | ||||||||
| Type of treatment | ||||||||||
| No treatment administered | 0 | 0.0 | 0 | 0.0 | 741 | 100.0 | 741 | 39.9 | ||
| Antiviral + monoclonal antibody | ||||||||||
| ± corticosteroids ± plasma | 141 | 14.1 | 0 | 0.0 | 0 | 0.0 | 141 | 7.6 | ||
| Antiviral ± corticosteroids ± plasma | 293 | 29.3 | 0 | 0.0 | 0 | 0.0 | 293 | 15.8 | ||
| Corticosteroids | 242 | 24.2 | 0 | 0.0 | 0 | 0.0 | 242 | 13.0 | ||
| Monoclonal antibodies | ||||||||||
| ± plasma ± corticosteroids | 305 | 30.5 | 0 | 0.0 | 0 | 0.0 | 305 | 16.4 | ||
| Nirmatrelvir combination therapy | ||||||||||
| ± corticosteroids ± plasma | 0 | 0.0 | 24 | 20.5 | 0 | 0.0 | 24 | 1.3 | ||
| 1st line | 0 | 0.0 | 7 | 6.0 | 0 | 0.0 | 7 | 0.4 | ||
| Other line | 0 | 0.0 | 17 | 14.5 | 0 | 0.0 | 17 | 0.9 | ||
| Nirmatrelvir monotherapy | ||||||||||
| ± corticosteroids ± plasma | 0 | 0.0 | 93 | 79.5 | 0 | 0.0 | 93 | 5.0 | ||
| 1st line | 0 | 0.0 | 93 | 79.5 | 0 | 0.0 | 93 | 5.0 | ||
| Plasma ± corticosteroids | 20 | 2.0 | 0 | 0.0 | 0 | 0.0 | 20 | 1.1 | ||
| Outcome | 0.027 | 0.016 | ||||||||
| Days from COVID-19 onset to final day of follow up/death | 26 (12–47) [0–219] | 35 (16–64) [0–191] | 27 (12–46) [0–214] | 27 (13–48) [0–219] | ||||||
| Alive | 853 | 85.2 | 0.023 | 109 | 93.2 | 0.666 | 701 | 94.6 | 1663 | 89.5 |
| Dead | 148 | 14.8 | 8 | 6.8 | 40 | 5.4 | 196 | 10.5 | ||
| Days from COVID-19 onset to final day of follow up | 29 (14–51) [0–219] | 35 (15–63) [0–191] | 28 (13–46) [0–214] | 29 (14–50) [0–219] | ||||||
| Days from COVID-19 onset to death | 16 (8–28) [0–109] | 48.5 (28.5–83) [14–156] | 12 (4–25) [0–127] | 16 (7–30) [0–156] | ||||||
| Reason for death | 0.177 | 0.588 | ||||||||
| COVID-19 | 84 | 8.4 | 2 | 1.7 | 17 | 2.3 | 103 | 5.5 | ||
| COVID-19 | ||||||||||
| + hematological malignancy | 46 | 4.6 | 4 | 3.4 | 11 | 1.5 | 61 | 3.3 | ||
| Hematological maligancies | ||||||||||
| +/− other reasons | 14 | 1.4 | 2 | 1.7 | 9 | 1.2 | 25 | 1.3 | ||
| Other reasons | 4 | 0.4 | 0 | 0.0 | 3 | 0.4 | 7 | 0.4 | ||
This table includes patients from institutions worldwide.
COVID-19, coronavirus 2019 disease; ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.